INmune Bio (INMB) Competitors $4.40 -0.02 (-0.45%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INMB vs. KRRO, SIGA, CRVS, KALV, AURA, SANA, IGMS, RGNX, GHRS, and TSHAShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Korro Bio (KRRO), SIGA Technologies (SIGA), Corvus Pharmaceuticals (CRVS), KalVista Pharmaceuticals (KALV), Aura Biosciences (AURA), Sana Biotechnology (SANA), IGM Biosciences (IGMS), REGENXBIO (RGNX), GH Research (GHRS), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Korro Bio SIGA Technologies Corvus Pharmaceuticals KalVista Pharmaceuticals Aura Biosciences Sana Biotechnology IGM Biosciences REGENXBIO GH Research Taysha Gene Therapies Korro Bio (NASDAQ:KRRO) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Which has higher valuation and earnings, KRRO or INMB? INmune Bio has lower revenue, but higher earnings than Korro Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$14.07M29.08-$81.17MN/AN/AINmune Bio$42K2,322.78-$30.01M-$2.18-2.02 Do insiders & institutionals believe in KRRO or INMB? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 5.4% of Korro Bio shares are held by company insiders. Comparatively, 35.2% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer KRRO or INMB? INmune Bio received 117 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 76.09% of users gave INmune Bio an outperform vote. CompanyUnderperformOutperformKorro BioOutperform Votes23100.00% Underperform VotesNo VotesINmune BioOutperform Votes14076.09% Underperform Votes4423.91% Is KRRO or INMB more profitable? Korro Bio has a net margin of 0.00% compared to INmune Bio's net margin of -26,333.59%. Korro Bio's return on equity of -50.25% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -50.25% -38.48% INmune Bio -26,333.59%-117.48%-78.96% Do analysts recommend KRRO or INMB? Korro Bio currently has a consensus price target of $142.17, suggesting a potential upside of 225.55%. INmune Bio has a consensus price target of $20.00, suggesting a potential upside of 354.55%. Given INmune Bio's higher possible upside, analysts clearly believe INmune Bio is more favorable than Korro Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17INmune Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer KRRO or INMB? In the previous week, Korro Bio had 1 more articles in the media than INmune Bio. MarketBeat recorded 1 mentions for Korro Bio and 0 mentions for INmune Bio. Korro Bio's average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score. Company Overall Sentiment Korro Bio Neutral INmune Bio Neutral Which has more volatility and risk, KRRO or INMB? Korro Bio has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. SummaryKorro Bio beats INmune Bio on 11 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.56M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-2.0246.7391.3417.19Price / Sales2,322.78411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book2.133.894.794.78Net Income-$30.01M-$42.21M$120.07M$225.60M7 Day Performance-7.37%-2.14%-1.89%-1.24%1 Month Performance-7.95%4.21%11.45%3.36%1 Year Performance-57.28%18.40%30.61%16.58% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.4803 of 5 stars$4.40-0.5%$20.00+354.5%-55.7%$97.56M$42,000.00-2.0210High Trading VolumeKRROKorro Bio1.2664 of 5 stars$47.75+1.9%$142.17+197.7%-21.8%$447.42M$14.07M0.0070SIGASIGA Technologies1.6095 of 5 stars$6.26+1.3%N/A+4.6%$446.96M$139.92M5.1540Positive NewsGap DownCRVSCorvus Pharmaceuticals2.2319 of 5 stars$6.95-5.8%$12.83+84.7%+219.9%$446.59MN/A-7.8030Options VolumeNews CoverageKALVKalVista Pharmaceuticals3.9512 of 5 stars$8.92+2.6%$24.00+169.1%-24.0%$440.83MN/A-2.39150Analyst ForecastAURAAura Biosciences2.4687 of 5 stars$8.77+4.3%$23.00+162.3%-3.1%$438.07MN/A-4.8650News CoverageSANASana Biotechnology2.0915 of 5 stars$1.96+3.7%$13.50+588.8%-59.8%$437.61MN/A-1.35328IGMSIGM Biosciences4.5517 of 5 stars$7.27+1.4%$17.75+144.2%-12.2%$432.30M$2.92M-2.11190News CoverageRGNXREGENXBIO4.5991 of 5 stars$8.55+3.3%$35.27+312.5%-58.4%$423.57M$90.24M-1.65344GHRSGH Research1.1295 of 5 stars$8.10+4.7%$35.67+340.3%+28.8%$421.43MN/A-9.8010TSHATaysha Gene Therapies3.6226 of 5 stars$2.03-1.9%$6.63+226.4%+30.3%$416.03M$15.45M3.29180 Related Companies and Tools Related Companies Korro Bio Competitors SIGA Technologies Competitors Corvus Pharmaceuticals Competitors KalVista Pharmaceuticals Competitors Aura Biosciences Competitors Sana Biotechnology Competitors IGM Biosciences Competitors REGENXBIO Competitors GH Research Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INMB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
